Madrigal (MDGL) Q2 2026 earnings review
Record Volume Masks Rising Costs of Commercialization
Madrigal rebounded powerfully from a seasonally weak Q1, delivering record Rezdiffra net sales of $364.3M (+71% YoY). The active patient base surged past 49,000, confirming that market demand remains highly robust despite new GLP-1 competition. However, the path to profitability remains obscured. Aggressive commercial expansion—including a direct-to-consumer campaign and endocrinology field force—pushed SG&A to $289.4M, resulting in a widened net loss of $57.9M. While the top-line trajectory is undeniable, margin pressures from increased royalty payments and inventory write-downs require investor attention.
🐂 Bull Case
Active patients essentially doubled YoY from ~23,000 to over 49,000. The rapid adoption confirms Rezdiffra's status as the foundational MASH standard of care, completely unfazed by competing metabolic injectable therapies.
Three new USPTO patents spanning F2-F3 dosing and F4c (cirrhosis) effectively lock in Madrigal’s commercial moat until 2042-2045, ensuring decades of unencumbered revenue generation.
🐻 Bear Case
Cost of Sales exploded 339% YoY to $40.0M, drastically outpacing the 71% revenue growth. Royalties to Roche and an unexplained inventory write-down represent a material drag on gross profitability.
The sheer weight of scaling SG&A ($289M for the quarter) highlights the immense capital required to 'wire the system' for endocrinologists and run national DTC campaigns, deferring GAAP profitability indefinitely.
⚖️ Verdict: ⚪
Neutral. The volume and revenue execution is exceptional, but the skyrocketing Cost of Sales and ballooning operating expenses contradict the pure-margin biotech thesis. Growth is fully intact, but it is currently being bought at a premium.
Key Themes
Patient Adoption is Accelerating
Madrigal added roughly 6,750 net new active patients in Q2, bringing the total base past 49,000. This Reversing dynamic from Q1's insurance-driven deceleration proves that underlying physician conviction and patient persistence remain exceptionally strong. With market diagnosis rates hovering near 10%, the volume ceiling remains years away.
Next-Gen Tech: MGL-2086 GLP-1 Integration
Madrigal initiated Phase 1 dosing for MGL-2086, its proprietary oral GLP-1. This is a critical technological leap. By pairing Rezdiffra with a mechanism proven to generate modest weight loss (≥5%), Madrigal aims to compound antifibrotic efficacy and create an all-oral, best-in-disease combination therapy, directly blunting the threat of injectable GLP-1s.
Macro Tailwinds: Diagnostic Funnel Expansion
The systemic under-penetration of MASH diagnostics presents a massive macro opportunity. Madrigal is proactively addressing this by launching the 'MASH Across America' experiential campaign. By increasing grassroots disease awareness, they are expanding the addressable market at the very top of the diagnostic funnel, ensuring a sustainable pipeline of future patients.
Cost of Sales Explosion
Accelerating dramatically. Cost of Sales surged from $9.1M in 25Q2 to $40.0M in 26Q2, a 339% YoY increase that starkly contradicts the positive revenue narrative. Management attributed this to increased royalties payable to Roche and a write-down of work-in-process inventory. This signals potential manufacturing friction and margin-dilutive contractual obligations.
Operating Expenses Skyrocketing
Accelerating. SG&A hit an eye-watering $289.4M (up 47% YoY), while R&D climbed to $91.2M. The massive commercial infrastructure required to maintain this launch trajectory—specifically the endocrinology field force and DTC marketing—means bottom-line profitability remains entirely out of view despite $1.3B in trailing-twelve-month sales.
Gross-to-Net Pressures
Stable but restrictive. While not explicitly modeled in the Q2 press release, management's prior guidance dictates that gross-to-net discounts have permanently stepped up to the mid-to-high 30s. This structural reality means Madrigal must drive exponentially higher script volumes simply to maintain its current net sales trajectory.
Other KPIs
Decelerating YoY (widening from a loss of $42.3M in 25Q2) but representing a sequential improvement from the $94.4M net loss in 26Q1. The loss was heavily influenced by a $25.0M one-time, upfront business development expense recorded in R&D.
Stable, but slowly declining from $988.6M at the end of FY25 and $817.9M at the end of 26Q1. The balance sheet remains sufficiently fortified to fund the commercial scale-up and pipeline buildout without immediate dilution risks.
Key Questions
Inventory Write-Down Mechanics
Can you provide specific details regarding the write-down of work-in-process inventory? Is this an isolated manufacturing anomaly, or are there underlying complexities in scaling Rezdiffra production?
Roche Royalty Structure
With trailing twelve-month revenues hitting $1.3B, Cost of Sales rose substantially due to Roche royalties. Does this royalty structure tier upwards with higher sales volumes, and what long-term gross margin should we model?
Operating Leverage Threshold
With SG&A rapidly approaching $300M a quarter to support the endocrinology expansion and DTC campaigns, at what annualized revenue run-rate do you expect to start seeing meaningful operating leverage and a clear transition to GAAP profitability?
MGL-2086 Profile
As MGL-2086 advances through Phase 1, what specific safety and tolerability differentiation are you looking for to ensure it pairs cleanly with Rezdiffra without compounding GI-related adverse events?